Insight

Karen Bedirian: Happy to share that IMMONC received regulatory approval to conduct a trial of BAL+BOT among patients with metastatic non-small cell lung cancer

Photo of Karen Bedirian from immonc.org

Feb 14, 2024, 13:40

Karen Bedirian: Happy to share that IMMONC received regulatory approval to conduct a trial of BAL+BOT among patients with metastatic non-small cell lung cancer

Karen Bedirian, Projects Director at Immune Oncology Research Institute, shared on LinkedIn:

“Happy to share that IMMONC received regulatory approval to conduct a clinical trial of BAL+BOT among patients with metastatic non-small cell lung cancer.
We received the approval of the Center of Drug and Medical Technology in just 30 working days and the approval of the MoH Ethics Committee in just 9 working days.

Grateful for the team’s efforts. Immune Oncology Research Institute
Thank you Agenus for the continued support.”

Source: Karen Bedirian/LinkedIn

Agenus BAL+BOT Balstilimab botensilimab cancer IMMONC Immune Oncology Research Institute Karen Bedirian metastatic non-small cell lung cancer OncoDaily Oncology

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer

Black History Month 2025: Honoring Contributions to Oncology